Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 8/20 | 0.52 |
| ▸ | CES1 | P23141 | 7/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291901 | 0.92 | RAB9A (0.48) | CES2CES1RAB9AALDH1A1KMT2A | |
| SCHEMBL4291907 | 0.92 | RAB9A (0.48) | CES2CES1RAB9AALDH1A1KMT2A | |
| SCHEMBL7383383 | 0.90 | ALDH1A1 (0.58) | CES2CES1RAB9AALDH1A1KMT2A | |
| SCHEMBL5318227 | 0.90 | ALDH1A1 (0.58) | CES2CES1RAB9AALDH1A1KMT2A | |
| SCHEMBL1081436 | 0.86 | ALDH1A1 (0.45) | CES2CES1RAB9AALDH1A1KMT2A | |
| SCHEMBL1081432 | 0.86 | ALDH1A1 (0.45) | CES2CES1RAB9AALDH1A1KMT2A | |
| SCHEMBL8190510 | 0.85 | POLB (0.57) | CES2CES1RAB9AALDH1A1KMT2A | |
| SCHEMBL8190513 | 0.85 | POLB (0.57) | CES2CES1RAB9AALDH1A1KMT2A | |
| SCHEMBL3452959 | 0.83 | RAB9A (0.56) | RAB9AALDH1A1KMT2ALMNAGAA | |
| SCHEMBL3452956 | 0.83 | RAB9A (0.56) | RAB9AALDH1A1KMT2ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742904-B1 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | UNIV CALIFORNIA (US) | 2012-10-31 | — | — | EP | disclosed |
| US-7825278-B2 | Substituted enaminones, their derivatives and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | OXFORD FINANCE CORPORATION | 2008-03-13 | — | — | US | disclosed |
| EP-1742904-A4 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | UNIV CALIFORNIA (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1742904-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108347-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | GABRB2, GABRB1, GABRB3 | CES2 1007/4885CES1 1398/4885RAB9A 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.